Protection from psoriasis-related thrombosis following inhibition of IL-23 or IL-17A

Psoriasis patients experience chronic systemic skin inflammation and develop cardiovascular comorbidities that shorten their lifespan. Whether cardiovascular disease is improved by treatment with current biologics that target disease-specific pathways is unclear. KC-Tie2 mice develop psoriasiform skin inflammation with increases in IL-23 and IL-17A and proinflammatory monocytosis and neutrophilia that precedes development of carotid artery thrombus formation. To examine whether targeted blockade of IL-23 or IL-17A in KC-Tie2 psoriasis mice improves cardiovascular outcomes, mice were treated systemically for 6 weeks with antibodies targeting IL-17A, IL-17RA, IL-12/23p40, or IL-23p19.

http://www.jidonline.org/article/S0022-202X(17)32978-0/fulltext?rss=yes

Source: Journal of Investigative Dermatology - September 23, 2017 Category: Dermatology Authors: Yumeng Li, Jackelyn B. Golden, Maya I. Camhi, Xiufen Zhang, Yi Fritz, Doina Diaconu, Tammy L. Ivanco, Daniel I. Simon, Kristine Kikly, Thomas S. McCormick, Yunmei Wang, Nicole L. Ward Tags: Original Article Source Type: research